SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
-------------------------------
Date of report (Date of earliest event reported):
NOVEMBER 9, 2004 (NOVEMBER 8, 2004)
-----------------------------------
DOV PHARMACEUTICAL, INC.
----------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE 000-49730 22-3374365
(State or other jurisdiction (Commission file number) (IRS employer
of incorporation) identification no.)
433 HACKENSACK AVENUE, HACKENSACK, NJ 07601
(Address of principal executive offices) (Zip code)
---------------------------------------------------
(201) 968-0980
(Registrant's telephone number, including area code)
TABLE OF CONTENTS
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
EXHIBIT 99.1
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION.
On November 8, 2004, DOV Pharmaceutical, Inc. announced its financial
results for the quarter ended September 30, 2004. The text of the press release
issued in connection with the announcement is filed as Exhibit 99.1 to this
Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in
this Current Report of Form 8-K, including Exhibit 99.1, shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liability of that section, except as
expressly set forth by specific reference in such a filing, or registrant
incorporates it by reference into a filing under the Securities Act of 1933, as
amended.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS. The following exhibits are filed herewith:
- --------------------------------------------------------------------------------
Exhibit No. Description
- --------------------------------------------------------------------------------
99.1 Press Release dated November 8, 2004
- --------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DOV Pharmaceutical, Inc.
Date: November 9, 2004 /s/ Arnold Lippa
----------------------------------------
Arnold Lippa
Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Title
- ------ -----
99.1 Press release dated November 8, 2004, issued by registrant